Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma

NEXT STORY
Revive Confirms No Material Undisclosed Information
PREV STORY
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma

NEXT STORY
Revive Confirms No Material Undisclosed Information
PREV STORY
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual Meeting

RANCHO CORDOVA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) ...

author_avatar
NASDAQ Market News

Global Clinical Diagnostics Market, By Type of Test, By Product, By Application, By Region, Competition, Forecast & Opportunities, 2025

author_avatar
NASDAQ Market News

Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020

author_avatar
NASDAQ Market News